References
- CDC. Changing patterns of groups at high risk for hepatitis B in the United States. MMWR 1988; 37: 429–437
- Bhatti N, Gilson R, Beecham M, Williams P, Matthews M, Tedder R, Weller I. Failure to deliver hepatitis B vaccine: confessions from a genitourinary medicine clinic. BMJ 1991; 303: 97–101
- Mulley A, Silverstein M, Dienstag J. Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. N Engl J Med 1982; 307: 644–652
- Adler M, Belsey E, McCutchan B, Mindel A. Should homosexuals be vaccinated against hepatitis-B virus? Cost and benefit assessment. BMJ 1983; 286: 1621–1624
- Hamilton J. Hepatitis B virus vaccine. An analysis of its potential use in medical workers. JAMA 1983; 250: 2145–2150
- Rivera F, Lissen E, Vazquez R, Arrayo F, Sánchez-Quijano A, Garcíade Pesquera F, Leal M, Lozano F, Cordero A, Herrera C, Pascual A, Andreu-Kern V. Analisi costobeneficio de un programme de vacination contra la hepatitis-B en personal sanitario hospitalario. Med Clin (Barc) 1984; 83: 611–614
- Lange W, Masihi K. Epidemiology and economic importance of hepatitis B in the Federal Republic of Germany. Postgrad Med J 1987; 63(Suppl 2)21–26
- Jönsson B. Cost-benefit analysis of hepatitis B vaccination. Postgrad Med J 1987; 63(Suppl 2)27–32
- Margolis H, Schatz G, Kane M. Development of recommendations for control of hepatitis B virus infections: the role of cost analysis. Vaccine 1990; 8(Suppl)81–85
- Ginsberg G, Berger S, Shouval D. Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity. Bull WHO 1992; 70: 757–767